Estrogen insensitivity syndrome

Source: Wikipedia, the free encyclopedia.
Estrogen insensitivity syndrome
Other namesEIS; Complete estrogen insensitivity syndrome; CEIS[1]
EIS results when the function of the estrogen receptor alpha (ERα) is impaired. The ERα protein (pictured) mediates most of the effects of estrogens in the human body.
SpecialtyEndocrinology

Estrogen insensitivity syndrome (EIS), or estrogen resistance, is a form of

symptomatology to EIS.[4]

EIS is an extremely rare occurrence.[5][6] As of 2016, there have been three published reports of EIS, involving a total of five individuals.[6] The reports include a male case published in 1994,[7][8] a female case published in 2013,[5][9] and a familial case involving two sisters and a brother which was published in 2016.[6]

EIS is analogous to androgen insensitivity syndrome (AIS), a condition in which the androgen receptor (AR) is defective and insensitive to androgens, such as testosterone and dihydrotestosterone (DHT). The functional opposite of EIS is hyperestrogenism, for instance that seen in aromatase excess syndrome.

History

Male case

In 1994, a 28-year-old man was diagnosed with EIS after presenting to an

morning erections and nocturnal emissions.[7]

bone-specific alkaline phosphatase levels were both substantially elevated (18.7–21.6 ng/mL and 33.3–35.9 ng/mL, respectively).[7]

Treatment with up to very high doses of estradiol (fourteen 100-μg Estraderm patches per week) had no effect on any of his symptoms of hypoestrogenism, did not produce any estrogenic effects such as gynecomastia, and had no effect on any of his physiological parameters (e.g., hormone levels or bone parameters), suggesting a profile of complete estrogen insensitivity syndrome.[7]

Female case

In 2013, an 18-year-old woman with EIS was reported.

hemorrhagic cysts as the cause of the lower abdominal pain.[9]

ERβ could not be excluded.[9]

The patient had a small

Treatment of the patient with

hypothalamic-pituitary-gonadal axis hyperactivity and ovarian pathology.[9]

Familial case

In 2016, a familial instance of EIS involving three siblings was reported.

autosomal recessive manner and that a single normal allele is sufficient to achieve normal puberty and fertility, which is consistent with what has been observed in ERα knockout mice.[6]

All three siblings presented with

chest acne, which could be attributed to hyperandrogenism (see below).[6] All three siblings showed markedly delayed bone maturation for their chronological ages.[6] The older sister was of normal height, while the younger sister was tall.[6]

In all three siblings,

axis would account for the elevated estradiol and gonadotropin levels in the siblings and for the ovarian enlargement and cyst formation in the sisters.[6]

All three siblings were homozygous for a

ligand-binding domain (LBD) of the ERα protein.[6] This is a critical residue that is completely conserved among species and in the androgen receptor (AR) and mineralocorticoid receptor (MR).[6] Mutations involving the corresponding residue in the AR and MR have previously been associated with androgen insensitivity syndrome (AIS) and diminished sensitivity to mineralocorticoids, respectively.[6]

hydroxyl groups of estradiol are anchored by the Glu353 and Arg394, and His524 residues of the ERα protein, respectively.[6] In the mutated ERα, the His394 residue is unable to properly anchor estradiol, which results in the dramatically reduced sensitivity and response of the receptor to estradiol relative to the normal ERα.[6] A group of other ERα agonists that included ethinylestradiol, diethylstilbestrol, tamoxifen, clomifene, and raloxifene were tested in their ability to promote transcriptional activity of the mutated ERα, but none of them were found to be more efficacious than estradiol in activating the mutated receptor and hence in overcoming the estrogen insensitivity of the siblings.[6]

As the sisters had very high, supraphysiological levels of circulating estradiol, the authors cautioned that it could not be ruled out that estradiol may have exerted some functional influence on their phenotypes via signaling through the

GPER (i.e., that not all of the observed phenotypes may have simply been due to loss of ERα signaling).[6] Moreover, the authors noted that this might partially explain the variability in the phenotypes.[6]

Further cases

Two more cases of EIS in sisters were reported in 2022.[15]

Research

EIS can be experimentally induced in animals via

brittle.[citation needed] Variations in these patterns can be achieved by selectively disabling the ERα or ERβ.[16]

The following sections are an extensive though partial/incomplete list of deficits observed in ERKO mice.[16]

αERKO mice

Females

Males

βERKO mice

Females

  • The uterus, vagina, and oviducts are normal.[16] The ovary is normal prior to puberty, and there is still no gross aberrant phenotype during adulthood.[16] However, there is partial anovulation and subfertility, which is due to ovarian defects, namely compromised follicular maturation via loss of estradiol signaling in ovarian granulosa cells.[16]
  • The mammary gland appears to be normal.[16]
  • Body weight and
    fat distribution appear to be normal.[16]
  • Increased

Males

GPERKO mice

GPER knockout mice have also been generated, and exhibit

glucose intolerance, differences in mammary carcinogenesis and metastasis, and differences in central nervous system function.[19][20]

Androgen insensitivity syndrome

In contrast to EIS,

X-linked recessive condition and thus carried over, by females, into future generations (although the most severe form, complete androgen insensitivity syndrome (CAIS), results in sterility, and hence cannot be passed on to offspring). EIS is not compatible with reproduction, thus each occurrence in humans would have to be a de novo mutation and is not transmitted to offspring.[citation needed
]

References

Further reading

External links